Bremelanotide
Mechanism
This one works your brain, not your blood vessels: a melanocortin-4 receptor agonist acting straight on the hypothalamus, the desire switch itself, not the plumbing downstream. That's the whole difference between this and a PDE5 inhibitor. One turns on wanting it, the other just handles the mechanics once you already do.
Key Benefit
FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Produces meaningful improvement in desire and distress scores.
Evidence Base
FDA-approved as Vyleesi in 2019, on the strength of the RECONNECT trials. That approval is for women. Men only have phase II data behind them, nothing near what women's got on record.
Route & Rationale
Subcutaneous injection (as needed). Central nervous system target requires systemic delivery. SC provides rapid onset (45 min).
Interactions
Transient blood pressure increase (~3 mmHg) and nausea common. Avoid with uncontrolled hypertension or naltrexone.
Regulatory Status
FDA-approved, specifically for premenopausal women with HSDD. That's the label. That's who it was studied on.
Gender Note
The approval covers premenopausal women only. That's what the FDA signed off on. Men using this for sexual dysfunction are working with phase II data and an off-label prescription, not the approval women get.
Hard Contraindications
Hypertension, Heart failure (CHF), Pregnancy/planning
For information and research purposes only. This is not medical advice and not a recommendation to use this substance. Discuss anything here with your healthcare provider.
